U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07204938) titled 'A Long-Term Study of Navenibart in Participants With Hereditary Angioedema' on Sept. 30.
Brief Summary: This is a Phase 3 multicenter trial in 2 parts to evaluate the long-term safety and efficacy of navenibart in adult and adolescent participants with hereditary angioedema (HAE) who participated in STAR-0215-301 (NCT06842823; ALPHA-ORBIT). Part 1 provides all participants with navenibart in a dose-controlled fashion; Part 2 introduces a personalized dosing option (PDO) for participants based on individual needs.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Hereditary Angioedema (HAE)
Intervention:
DRUG: n...